Form 4: West Pharmaceutical Services: Executive Stock Transactions
Statement of Changes in Beneficial Ownership
Shane Alden Campbell, SVP of Proprietary Segment at West Pharmaceutical Services, reported transactions involving restricted stock units and common stock.
Summary
- Shane Alden Campbell, Senior Vice President of the Proprietary Segment at West Pharmaceutical Services Inc. (WST), reported several transactions on May 12, 2026.
- These transactions involved the acquisition of common stock through the conversion of restricted stock units (RSUs) and the disposition of common stock.
- Specifically, 295.995 RSUs were acquired and converted into common stock, and another 473.593 RSUs were also acquired and converted.
- Additionally, 84.329 shares of common stock were disposed of at a price of $312.07, and another 134.927 shares were disposed of at the same price.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it represents routine executive stock transactions rather than significant strategic shifts or performance indicators.
Positives
- Acquisition of common stock through the conversion of restricted stock units, indicating potential long-term incentive alignment.
- The reporting person, Shane Alden Campbell, holds a significant number of shares (747.7234 shares) after these transactions, suggesting continued investment in the company.
Negatives
- Disposition of a notable number of common stock shares (84.329 and 134.927) by a key executive, which could be interpreted as a reduction in direct ownership.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions, providing transparency into insider activity. The specific details of RSUs converting to stock and subsequent sales are common within the pharmaceutical services industry as part of executive compensation and liquidity management.
Stakeholder Impact
- Shareholders: The sale of shares by an executive may be perceived negatively, though it is a common practice for liquidity and diversification. The acquisition of stock via RSUs aligns executive interests with long-term company performance.
- Employees: The transactions reflect the company's executive compensation structure, which may influence employee morale and retention strategies.
- Creditors: No direct impact is indicated.
Key Dates
| Date | Description |
|---|---|
| 05/12/2026 | Date of earliest transaction and transaction date for stock acquisitions and dispositions. |
| 05/14/2026 | Date of signature for the filing. |
Keywords
Form 4, SEC Filing, Stock Transaction, Restricted Stock Units, Beneficial Ownership, West Pharmaceutical Services, WST, Executive Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.